{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:20:18Z","timestamp":1789496418555,"version":"build-2803163510"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2020R1A2C3005834"],"award-info":[{"award-number":["NRF-2020R1A2C3005834"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2022R1A4A1030421"],"award-info":[{"award-number":["NRF-2022R1A4A1030421"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jconrel.2023.02.002","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T18:16:26Z","timestamp":1677089786000},"page":"730-744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Gastrointestinally absorbable lactoferrin-heparin conjugate with anti-angiogenic activity for treatment of brain tumor"],"prefix":"10.1016","volume":"355","author":[{"given":"Hae Hyun","family":"Hwang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Shik","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.02.002_bb0005","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1002\/ijc.25516","article-title":"Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008","volume":"127","author":"Ferlay","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","article-title":"The 2007 WHO classification of tumours of the central nervous system","volume":"114","author":"Louis","year":"2007","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0015","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and other malignant gliomas a clinical review","volume":"310","author":"Omuro","year":"2013","journal-title":"Jama-J Am Med Assoc"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/neuonc\/now207","article-title":"American Brain Tumor Association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008-2012","volume":"18","author":"Ostrom","year":"2016","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0305-7372(97)90019-0","article-title":"Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials","volume":"23","author":"Newlands","year":"1997","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0030","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/0006-2952(96)00077-9","article-title":"Retrovirus-mediated transfer of the human O-6-methylguanine-DNA methyltransferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents","volume":"51","author":"Wang","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0035","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/368258a0","article-title":"Mutation in the DNA mismatch repair gene homolog Hmlh1 is associated with hereditary nonpolyposis Colon-Cancer","volume":"368","author":"Bronner","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0040","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1586\/ern.10.32","article-title":"Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas","volume":"10","author":"Chamberlain","year":"2010","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0045","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","article-title":"FDA drug approval summary: bevacizumab (Avastin (R)) as treatment of recurrent glioblastoma Multiforme","volume":"14","author":"Cohen","year":"2009","journal-title":"Oncologist"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0050","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.critrevonc.2006.07.007","article-title":"Mechanisms of heparin induced anti-cancer activity in experimental cancer models","volume":"61","author":"Niers","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0055","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1021\/acs.bioconjchem.5b00133","article-title":"Size controlled heparin fragment-Deoxycholic acid conjugate showed anticancer property by inhibiting VEGF165","volume":"26","author":"Park","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0060","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jconrel.2006.12.031","article-title":"Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate","volume":"118","author":"Lee","year":"2007","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0065","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1021\/acsami.5b12347","article-title":"Antitumor and Antimetastasis activities of heparin-based micelle served as both carrier and drug","volume":"8","author":"Mei","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0070","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0092-8674(95)90112-4","article-title":"Regulation of growth-factor activation by proteoglycans - what is the role of the low-affinity receptors","volume":"83","author":"Schlessinger","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1042\/BSR20110077","article-title":"Binding affinities of vascular endothelial growth factor (VEGF) for heparin-derived oligosaccharides","volume":"32","author":"Zhao","year":"2012","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0080","doi-asserted-by":"crossref","first-page":"31508","DOI":"10.1074\/jbc.M414581200","article-title":"Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins","volume":"280","author":"Ashikari-Hada","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0085","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s13233-016-4111-8","article-title":"Antiangiogenic actions of heparin derivatives for cancer therapy","volume":"24","author":"Hwang","year":"2016","journal-title":"Macromol. Res."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0090","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1182\/blood.V83.11.3232.3232","article-title":"Immunoglobulin-G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor-4","volume":"83","author":"Kelton","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0095","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40138-013-0014-6","article-title":"Anticoagulants: a review of the pharmacology, dosing, and complications","volume":"1","author":"Alquwaizani","year":"2013","journal-title":"Curr Emerg Hosp Med Rep"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0100","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1002\/ijc.24239","article-title":"Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor","volume":"124","author":"Lee","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0105","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1007\/s11095-009-9989-9","article-title":"Antiangiogenic activity of orally absorbable heparin derivative in different types of cancer cells","volume":"26","author":"Lee","year":"2009","journal-title":"Pharm Res-Dord"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0110","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.biomaterials.2014.10.004","article-title":"LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways","volume":"37","author":"Chung","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0115","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1074\/jbc.M309868200","article-title":"Characterization of endostatin binding to heparin and heparan sulfate by surface plasmon resonance and molecular modeling - role of divalent cations","volume":"279","author":"Ricard-Blum","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0120","doi-asserted-by":"crossref","DOI":"10.1088\/0957-4484\/20\/45\/455104","article-title":"Gold and silver nanoparticles conjugated with heparin derivative possess anti-angiogenesis properties","volume":"20","author":"Kemp","year":"2009","journal-title":"Nanotechnology"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0125","first-page":"35","article-title":"Milk protein-shelled gold nanoparticles with gastrointestinally active absorption for aurotherapy to brain tumor","volume":"8","author":"Kim","year":"2022","journal-title":"Bioact Mater"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/s12951-021-01220-9","article-title":"A novel therapeutic strategy of multimodal nanoconjugates for state-of-the-art brain tumor phototherapy","volume":"20","author":"Kim","year":"2022","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0135","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/nure.12155","article-title":"Anticancer effects of lactoferrin: underlying mechanisms and future trends in cancer therapy","volume":"72","author":"Zhang","year":"2014","journal-title":"Nutr. Rev."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0140","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/0955-2863(93)90089-F","article-title":"Lactoferrin receptors in piglet small-intestine - Lactoferrin binding-properties, ontogeny, and regional distribution in the gastrointestinal-tract","volume":"4","author":"Gislason","year":"1993","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40005-021-00515-1","article-title":"Intestinal membrane transporter-mediated approaches to improve oral drug delivery","volume":"51","author":"Pangeni","year":"2021","journal-title":"J Pharm Invest"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0150","doi-asserted-by":"crossref","first-page":"7011","DOI":"10.1074\/jbc.274.11.7011","article-title":"Receptor-mediated transcytosis of lactoferrin through the blood-brain barrier","volume":"274","author":"Fillebeen","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0155","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3171\/2014.12.JNS14512","article-title":"In vitro and in vivo effect of human lactoferrin on glioblastoma growth","volume":"123","author":"Arcella","year":"2015","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0160","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40005-021-00530-2","article-title":"Oral cavity: an open horizon for nanopharmaceuticals","volume":"51","author":"Nguyen","year":"2021","journal-title":"J Pharm Invest"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0165","series-title":"Alternative routes of drug administration\u2014advantages and disadvantages (subject review)","first-page":"143","volume":"100","year":"1997"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0170","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1158\/0008-5472.CAN-09-0755","article-title":"Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis","volume":"69","author":"Pang","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0175","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-07-2799","article-title":"Capsiate, a nonpungent capsaicin-like compound, inhibits angiogenesis and vascular permeability via a direct inhibition of Src kinase activity","volume":"68","author":"Pyun","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0180","first-page":"47","article-title":"Methods of blood collection in the mouse","volume":"29","author":"Hoff","year":"2000","journal-title":"Lab Animal"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0185","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1215\/S1152851704000821","article-title":"Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme","volume":"7","author":"Giannini","year":"2005","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0190","doi-asserted-by":"crossref","first-page":"11973","DOI":"10.1002\/anie.201806770","article-title":"Dynamic covalent identification of an efficient heparin ligand","volume":"57","author":"Corredor","year":"2018","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0195","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41565-021-00858-8","article-title":"Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics","volume":"16","author":"Rennick","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0200","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1042\/bj20031253","article-title":"Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis","volume":"377","author":"Rejman","year":"2004","journal-title":"Biochem. J."},{"issue":"2019","key":"10.1016\/j.jconrel.2023.02.002_bb0205","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/bloodadvances.2019000975","article-title":"Guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients","volume":"3","author":"Anderson","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0210","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood-2011-05-353391","article-title":"Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4\/heparin antibodies","volume":"119","author":"Krauel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0215","doi-asserted-by":"crossref","DOI":"10.1186\/cc9993","article-title":"Heparin-induced thrombocytopenia in the ICU: an overview","volume":"15","author":"Sakr","year":"2011","journal-title":"Crit. Care"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0220","doi-asserted-by":"crossref","first-page":"411","DOI":"10.2131\/jts.32.411","article-title":"Toxicity screening after repeated dose of a newly developed oral heparin derivative in male cynomolgus monkeys","volume":"32","author":"Kim","year":"2007","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0225","first-page":"183","article-title":"Intraluminal pH of the human gastrointestinal tract","volume":"46","author":"Fallingborg","year":"1999","journal-title":"Dan. Med. Bull."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0230","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1517\/17425255.1.2.175","article-title":"Caco-2 cell permeability assays to measure drug absorption","volume":"1","author":"van Breemen","year":"2005","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0235","first-page":"48","article-title":"Inhibition of VEGFR2 activation and its downstream signaling to ERK1\/2 and calcium by thrombospondin-1 (TSP1): in silico investigation","volume":"8","author":"Bazzazi","year":"2017","journal-title":"Front. Physiol."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0240","article-title":"VEGFR-2 expression in glioblastoma multiforme depends on inflammatory tumor microenvironment","volume":"2015","author":"Jaal","year":"2015","journal-title":"Int J Inflam"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0245","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/sj.bjp.0706344","article-title":"A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity","volume":"146","author":"Takahashi","year":"2005","journal-title":"Brit. Aust. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0250","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0031-6997(24)01481-9","article-title":"The complex effects of heparins on cancer progression and metastasis in experimental studies","volume":"53","author":"Smorenburg","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0255","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1161\/01.ATV.0000090671.56682.D7","article-title":"Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight","volume":"23","author":"Khorana","year":"2003","journal-title":"Arterioscl Throm Vas"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0260","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.thromres.2007.06.015","article-title":"Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin","volume":"121","author":"Marchetti","year":"2008","journal-title":"Thromb. Res."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0265","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1160\/TH08-12-0832","article-title":"Anti-cancer properties of low-molecular-weight heparin: preclinical evidence","volume":"102","author":"Mousa","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0270","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0275","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1161\/01.CIR.103.24.2994","article-title":"Guide to anticoagulant therapy: heparin\u202f: a statement for healthcare professionals from the American Heart Association","volume":"103","author":"Hirsh","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0280","doi-asserted-by":"crossref","DOI":"10.1186\/s12987-017-0067-0","article-title":"Blood-brain barrier and foetal-onset hydrocephalus, with a view on potential novel treatments beyond managing CSF flow","volume":"14","author":"Guerra","year":"2017","journal-title":"Fluids Barriers Cns"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0285","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.7150\/thno.21254","article-title":"Current strategies for brain drug delivery","volume":"8","author":"Dong","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0290","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40005-021-00543-x","article-title":"Pharmaceutical application and development of fixed-dose combination: dosage form review","volume":"51","author":"Kim","year":"2021","journal-title":"J Pharm Invest"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0295","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1039\/C5TB02450A","article-title":"A multifunctional poly(curcumin) nanomedicine for dual-modal targeted delivery, intracellular responsive release, dual-drug treatment and imaging of multidrug resistant cancer cells","volume":"4","author":"Wang","year":"2016","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0300","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/19336918.2020.1767489","article-title":"The anti-cancer properties of heparin and its derivatives: a review and prospect","volume":"14","author":"Ma","year":"2020","journal-title":"Cell Adhes. Migr."},{"key":"10.1016\/j.jconrel.2023.02.002_bb0305","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.859633","article-title":"Next-generation anti-angiogenic therapies as a future prospect for glioma immunotherapy; from bench to bedside","volume":"13","author":"Shamshiripour","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0310","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s10014-013-0174-9","article-title":"Mechanism of chemoresistance against tyrosine kinase inhibitors in malignant glioma","volume":"31","author":"Nakada","year":"2014","journal-title":"Brain Tumor Pathol"},{"key":"10.1016\/j.jconrel.2023.02.002_bb0315","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s13311-016-0510-y","article-title":"New directions in anti-angiogenic therapy for glioblastoma","volume":"14","author":"Wang","year":"2017","journal-title":"Neurotherapeutics"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923000962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923000962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:48:54Z","timestamp":1759164534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923000962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":63,"alternative-id":["S0168365923000962"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.02.002","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gastrointestinally absorbable lactoferrin-heparin conjugate with anti-angiogenic activity for treatment of brain tumor","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}